Anastasios G. Konidaris's most recent trade in Amneal Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 458,716 Class A Common Stock done . Disclosure was reported to the exchange on March 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 458,716 | 657,304 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 458,716 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.31 per share. | 03 Mar 2026 | 229,817 | 427,487 (0%) | 0% | 13.3 | 3,058,864 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 57,339 | 57,340 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 57,339 | 208,599 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 49,982 | 87,963 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 45,290 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 45,290 | 167,442 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 43,982 | 471,469 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 28,538 | 212,886 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 28,538 | 85,617 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.31 per share. | 03 Mar 2026 | 24,251 | 184,348 (0%) | 0% | 13.3 | 322,781 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.30 per share. | 03 Mar 2026 | 22,035 | 449,434 (0%) | 0% | 13.3 | 293,066 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.31 per share. | 03 Mar 2026 | 16,182 | 151,260 (0%) | 0% | 13.3 | 215,382 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.31 per share. | 03 Mar 2026 | 14,298 | 198,588 (0%) | 0% | 13.3 | 190,306 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 72,622 | 72,622 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 72,622 | 72,622 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Sale of securities on an exchange or to another person at price $ 9.43 per share. | 13 Aug 2025 | 219,159 | 122,152 (0%) | 0% | 9.4 | 2,066,669 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Sale of securities on an exchange or to another person at price $ 9.22 per share. | 13 Aug 2025 | 161,365 | 460,517 (0%) | 0% | 9.2 | 1,487,785 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Sale of securities on an exchange or to another person at price $ 9.30 per share. | 13 Aug 2025 | 119,206 | 341,311 (0%) | 0% | 9.3 | 1,108,616 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Sale of securities on an exchange or to another person at price $ 8.91 per share. | 05 Mar 2025 | 100,000 | 621,882 (0%) | 0% | 8.9 | 891,000 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 228,310 | 228,310 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 181,159 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 181,159 | 793,061 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 114,155 | 114,154 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 92,663 | 700,398 (0%) | 0% | 8.8 | 811,728 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 57,340 | 114,679 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 57,340 | 636,276 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 45,290 | 45,290 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 45,290 | 595,309 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 43,981 | 744,379 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 43,981 | 131,945 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 24,374 | 611,902 (0%) | 0% | 8.8 | 213,516 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.84 per share. | 03 Mar 2025 | 22,497 | 721,882 (0%) | 0% | 8.8 | 198,873 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 16,373 | 578,936 (0%) | 0% | 8.8 | 143,427 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 36,197 | 563,513 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 36,197 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.67 per share. | 01 Mar 2025 | 13,494 | 550,019 (0%) | 0% | 8.7 | 116,993 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2024 | 87,720 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2024 | 87,720 | 558,106 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.31 per share. | 12 Mar 2024 | 30,790 | 527,316 (0%) | 0% | 5.3 | 163,495 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 351,852 | 351,852 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 175,926 | 175,926 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 57,339 | 172,019 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 57,339 | 490,512 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 45,290 | 449,070 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 45,290 | 90,580 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 36,197 | 417,037 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 36,197 | 36,197 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 01 Mar 2024 | 20,126 | 470,386 (0%) | 0% | 5.5 | 110,089 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 01 Mar 2024 | 15,897 | 433,173 (0%) | 0% | 5.5 | 86,957 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 01 Mar 2024 | 13,257 | 403,780 (0%) | 0% | 5.5 | 72,516 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2023 | 87,719 | 87,720 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2023 | 87,719 | 380,840 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 458,716 | 458,716 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 229,358 | 229,358 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 45,289 | 135,870 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 45,289 | 293,121 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 36,197 | 72,394 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 36,197 | 247,832 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2022 | 87,719 | 211,635 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2022 | 87,719 | 175,439 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 362,318 | 362,318 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 181,159 | 181,159 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 36,197 | 108,591 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 36,197 | 123,916 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2021 | 87,719 | 263,158 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2021 | 87,719 | 87,719 (0%) | 0% | - | Class A Common Stock |